Kristin Abate's most recent trade in Karyopharm Therapeutics Inc was a trade of 46 Common Stock done . Disclosure was reported to the exchange on Sept. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2025 | 46 | 10,431 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 6.43 per share. | 12 Sep 2025 | 23 | 10,408 (0%) | 0% | 6.4 | 148 | Common Stock |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 6.75 per share. | 03 Sep 2025 | 12 | 9,463 (0%) | 0% | 6.8 | 81 | Common Stock |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 22 Jul 2025 | 238 | 9,475 (0%) | 0% | 4 | 952 | Common Stock |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 04 Mar 2025 | 571 | 9,713 (0%) | 0% | 6.3 | 3,592 | Common Stock |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 1,866 | 1,866 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Kristin Abate | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 933 | 10,284 (0%) | 0% | 0 | Common Stock |